Alzheimer's disease

出典: meddic

アルツハイマー病


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/03/23 21:09:13」(JST)

wiki en

[Wiki en表示]

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2017/02/19 20:04:36」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • In vivo imaging of human adipose-derived stem cells in Alzheimer's disease animal model.
  • Ha S, Ahn S, Kim S, Joo Y, Chong YH, Suh YH, Chang KA.Author information Gachon University of Medicine and Science, Department of Pharmacology, Incheon, Republic of Korea.AbstractABSTRACT. Stem cell therapy is a promising tool for the treatment of diverse conditions, including neurodegenerative diseases such as Alzheimer's disease (AD). To understand transplanted stem cell biology, in vivo imaging is necessary. Nanomaterial has great potential for in vivo imaging and several noninvasive methods are used, such as magnetic resonance imaging, positron emission tomography, fluorescence imaging (FI) and near-infrared FI. However, each method has limitations for in vivo imaging. To overcome these limitations, multimodal nanoprobes have been developed. In the present study, we intravenously injected human adipose-derived stem cells (hASCs) that were labeled with a multimodal nanoparticle, LEO-LIVE™-Magnoxide 675 or 797 (BITERIALS, Seoul, Korea), into Tg2576 mice, an AD mouse model. After sequential in vivo tracking using Maestro Imaging System, we found fluorescence signals up to 10 days after injection. We also found strong signals in the brains extracted from hASC-transplanted Tg2576 mice up to 12 days after injection. With these results, we suggest that in vivo imaging with this multimodal nanoparticle may provide a useful tool for stem cell tracking and understanding stem cell biology in other neurodegenerative diseases.
  • Journal of biomedical optics.J Biomed Opt.2014 May 1;19(5):51206. doi: 10.1117/1.JBO.19.5.051206.
  • ABSTRACT. Stem cell therapy is a promising tool for the treatment of diverse conditions, including neurodegenerative diseases such as Alzheimer's disease (AD). To understand transplanted stem cell biology, in vivo imaging is necessary. Nanomaterial has great potential for in vivo imaging and several
  • PMID 24297061
  • Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer's disease pathogenic factor.
  • Kim CB, Choi YY, Song WK, Song KB.Author information Electronics and Telecommunications Research Institute, Daejeon 305-700, Republic of Korea.AbstractABSTRACT. Alzheimer's disease (AD) is a neurodegenerative disorder that leads to a decline in cognitive and intellectual abilities and an irreversible mental deterioration. Based on multidisciplinary AD research, the most universally accepted hypotheses on AD pathogenesis are the intracerebral aggregate formation of beta-amyloid (Aβ) peptides. According to medical paradigmatic transition from medical treatment to early diagnostic prevention, scientists have considered physiological body fluid as a biomarker medium, in which the promising AD biomarkers could be verified. Recently, use of saliva has been considered as one of the diagnostic fluids over the past decade with meaningful diagnostic potential. We utilized saliva as a biomarker medium to correlate the salivary Aβ levels to AD pathological aspects, especially to the mild cognitive impairment group among AD patients, and to verify our detecting system to be sensitive enough for an early diagnostic tool. The identification of the salivary AD biomarkers using a facile microarraying method would motivate this study with the assistance of magnetically assembled antibody-conjugated nanoparticles and a photomultiplier tube as an optical detector. This simple magnetoimmunoassay system measures the photointensity generated by fluorescence, enables the quantification of the Aβ peptides from AD salivary samples, and consequently classifies the salivary Aβ levels into AD pathological aspects. This method demonstrates a facile approach enabling it to simply detect salivary Aβ peptides at a concentration as low as ∼20  pg/ml. It is expected that our simple magnetoimmunoassay system may have a potential as a detector for low-level Aβ peptides with weak-fluorescence emission.
  • Journal of biomedical optics.J Biomed Opt.2014 May 1;19(5):51205. doi: 10.1117/1.JBO.19.5.051205.
  • ABSTRACT. Alzheimer's disease (AD) is a neurodegenerative disorder that leads to a decline in cognitive and intellectual abilities and an irreversible mental deterioration. Based on multidisciplinary AD research, the most universally accepted hypotheses on AD pathogenesis are the intracerebral aggre
  • PMID 24297060
  • Testing synthetic amyloid-β aggregation inhibitor using single molecule atomic force spectroscopy.
  • Hane FT1, Lee BY1, Petoyan A2, Rauk A2, Leonenko Z3.Author information 1University of Waterloo, Department of Biology, 200 University Ave. West, Waterloo, Ontario, Canada N2L 3G1.2University of Calgary, Department of Chemistry, 2500 University Drive NW, Calgary, Alberta, Canada T2N 1N4.3University of Waterloo, Department of Biology, 200 University Ave. West, Waterloo, Ontario, Canada N2L 3G1; University of Waterloo, Department of Physics and Astronomy, 200 University Ave. West, Waterloo, Ontario, Canada N2L 3G1. Electronic address: zleonenk@uwaterloo.ca.AbstractAlzheimer's disease is a neurodegenerative disease with no known cure and few effective treatment options. The principal neurotoxic agent is an oligomeric form of the amyloid-β peptide and one of the treatment options currently being studied is the inhibition of amyloid aggregation. In this work, we test a novel pseudopeptidic aggregation inhibitor designated as SG1. SG1 has been designed to bind at the amyloid-β self-recognition site and prevent amyloid-β from misfolding into β sheet. We used atomic force spectroscopy, a nanoscale measurement technique, to quantify the binding forces between two single amyloid peptide molecules. For the first time, we demonstrate that single molecule atomic force spectroscopy can be used to assess the effectiveness of amyloid aggregation inhibitors by measuring the experimental yield of binding and can potentially be used as a screening technique for quick testing of efficacy of inhibitor drugs for amyloid aggregation.
  • Biosensors & bioelectronics.Biosens Bioelectron.2014 Apr 15;54:492-8. doi: 10.1016/j.bios.2013.10.060. Epub 2013 Nov 11.
  • Alzheimer's disease is a neurodegenerative disease with no known cure and few effective treatment options. The principal neurotoxic agent is an oligomeric form of the amyloid-β peptide and one of the treatment options currently being studied is the inhibition of amyloid aggregation. In this work, w
  • PMID 24321883

和文文献

  • Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer's disease diagnosis.
  • MCIとプレクリニカルAD概念の「いかがわしさ」 (特集 MCIとプレクリニカル・アルツハイマー病)
  • 非AD認知症の前段階 (特集 MCIとプレクリニカル・アルツハイマー病)

関連リンク

Learn about Alzheimer's disease, dementia and memory loss symptoms, causes and risk factors and understand their relation to normal aging and brain function. ... Alzheimer's is not a normal part of aging, although the greatest ...
Get the facts about Alzheimer’s disease, the most common cause of dementia. Learn about symptoms, causes, diagnosis, treatment, caregiving, and research. ... Alzheimer’s disease is an irreversible, progressive brain disorder that ...

関連画像

Understanding Alzheimer's Disease | Health  about Alzheimer’s disease | Fact FileDownload image Alzheimer S Disease PC  of Neuron Death in Alzheimer’s DiseaseAlzheimer's disease. Causes, symptoms cells may heal for Alzheimer’s disease


★リンクテーブル★
リンク元アルツハイマー病」「early-onset Alzheimer disease」「presenile dementia」「senile dementia」「late-onset Alzheimer disease
拡張検索familial Alzheimer's disease」「sporadic late-onset Alzheimer's disease
関連記事sing」「disease」「diseased」「S」「ss

アルツハイマー病」

  [★]

Alzheimer disease, Alzheimer's disease
(国試)Alzheimer病、(以下、厳密には同義ではない)→アルツハイマー型認知症アルツハイマー型痴呆 dementia of the Alzheimer type DAT, Alzheimer-type dementia Alzheimer type dementia ATD
Alzheimer型痴呆Alzheimer型認知症
ドネペジル認知症

概念

  • 進行性痴呆のなかで脳血管障害による痴呆に次いで多い (EPT.257)
  • 大脳皮質のびまん性萎縮が見られる (EPT.257)
  • 前脳基底野コリン作動性ニューロンの選択的な変性が見られ、アセチルコリンの産生が低下
  • 病理学的には、老人斑とアルツハイマー神経線維変化が見られる (EPT.257)

疫学

  • 認知症
  • 有病率:65歳以上5-10%。65~69歳:1.5%、85歳~:27.3%。
  • 認知症の半数がアルツハイマー病
  • アルツハイマー病の5-10%が家族性

アルツハイマーのリスクファクター

  • 高コレステロール
  • 血圧
  • ホモシステイン
  • 糖尿病。内臓脂肪(メタボリックシンドローム)
  • 喫煙

病理

  • 老人斑:細胞外にβアミロイドが沈着。
  • 神経原線維変化:細胞内にリン酸化されたタウ蛋白が凝集し、らせん構造をとる

症状

1. 中核症状

  • 1. 健忘(記銘力、記憶力)
  • 2. 見当識障害
  • 3. 思考力障害
  • 4. 計算力障害

2. 周辺症状

  • 不安、抑うつ、徘徊、不眠、妄想、せん妄、幻覚、暴行、焦燥感

他疾患との比較

  • 人格の変化
  • アルツハイマー病:晩期
  • Pick病:早期

未分類

  • 空間視の障害:例えば立方体の模写ができない。頭頂葉の障害とされる。
  • 着衣失行

検査

  • CT:側脳室の拡大、側頭葉の萎縮


[display]

  • MRI
  • T1:海馬の萎縮

./t_image/103/103D003.jpg

国試



early-onset Alzheimer disease」

  [★]

早期発症型アルツハイマー病早期発症型Alzheimer病

Alzheimer diseaseAlzheimer's diseaselate-onset Alzheimer diseasepresenile dementiasenile dementia

presenile dementia」

  [★]

Alzheimer diseaseAlzheimer's diseaseearly-onset Alzheimer diseaselate-onset Alzheimer diseasesenile dementia

senile dementia」

  [★] 老年認知症老年痴呆

Alzheimer diseaseAlzheimer's diseaseearly-onset Alzheimer diseaselate-onset Alzheimer diseasepresenile dementia

late-onset Alzheimer disease」

  [★]

Alzheimer diseaseAlzheimer's diseaseearly-onset Alzheimer diseasepresenile dementiasenile dementia

familial Alzheimer's disease」

  [★]

FAD

sporadic late-onset Alzheimer's disease」

  [★] 孤発性遅発性アルツハイマー病

sing」

  [★]

  • v.
過去sang-過去分詞sung

WordNet   license wordnet

「to make melodious sounds; "The nightingale was singing"」

WordNet   license wordnet

「deliver by singing; "Sing Christmas carols"」

WordNet   license wordnet

「produce tones with the voice; "She was singing while she was cooking"; "My brother sings very well"」

PrepTutorEJDIC   license prepejdic

「『歌う』;(…に)歌って聞かせる《+『to』(『for』)+『名』》;(楽器に合わせて)歌う《+『to』+『名』》・〈小鳥・虫などが〉『鳴く』,さえずる / 《文》(…を)詩(歌)にする,(詩(歌)を詠んで)賛美する《+『of』+『名』》・〈小川・風・弾丸・湯沸かし・耳などが〉歌うように鳴る・《米語》自白する;密告する・〈歌〉‘を'歌う・《副詞[句]を伴って》歌って…‘を'(…に)する・…‘を'唱える,詠唱する・《文》…‘を'詩(歌)にする,(詩(歌)に詠んで)賛美する・合唱の集い」


disease」

  [★]

  • n.
疾患illnessより厳密な概念。「ある臓器に明確な障害が確認され、それによって症状が出ているとはっきり説明できる場合」 (PSY.9)
特定の原因、病態生理、症状、経過、予後、病理組織所見が全てそろった場合 (PSY.9)
  • something that is very wrong with people's attitudes, way of life or with society.
ailailmentdisease entitydisorderillillnessmaladysicksickness
  • 注意
diseaseillnessdisorder


WordNet   license wordnet

「an impairment of health or a condition of abnormal functioning」

PrepTutorEJDIC   license prepejdic

「(体の)『病気』,疾患 / (精神・道徳などの)病気,病弊」

PrepTutorEJDIC   license prepejdic

「女性の話術芸人 =diseur」

diseased」

  [★]

WordNet   license wordnet

「caused by or altered by or manifesting disease or pathology; "diseased tonsils"; "a morbid growth"; "pathologic tissue"; "pathological bodily processes"」
morbid, pathologic, pathological

PrepTutorEJDIC   license prepejdic

「病気にかかった / 病的な,不健全な(morbid)」

S」

  [★]

WordNet   license wordnet

「the 19th letter of the Roman alphabet」
s

PrepTutorEJDIC   license prepejdic

「sulfurの化学記号 / {略}South[ern]」

ss」

  [★]

single strandsingle-strandsingle-stranded





★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡